Table: Astellas -2024/25 group forecast(IFRS)
Jan 24 (Reuters) -
Astellas Pharma Inc.
CONSOLIDATED EARNINGS ESTIMATES
(in billions of yen unless specified)
Full Year to Full Year to
Mar 31, 2025 Mar 31, 2025
LATEST PREVIOUS
FORECAST FORECAST
Sales 1.90 trln 1.80 trln
Operating 11.00 80.00
PreTax 1.00 70.00
Net 14.00 50.00
EPS Basic 7.82 yen 27.93 yen
NOTE - Astellas Pharma Inc..(Figures are reported based on international accounting rules (IFRS).)
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)